Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
The Japanese market for aortic repair devices will expand at a moderate rate, driven primarily by endovascular procedure volume growth and continued development and adoption of aortic stent grafts. However, endovascular procedure volume growth will be hindered to some extent by unavailability of certain aortic stent graft brands that are available in other established markets but not in Japan.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for aortic repair devices in Japan across a 10-year period.
Aortic repair can be performed using endovascular, surgical, or hybrid procedures.
Which methods are preferred for which indications?
To what extent are hybrid aortic repair procedures being performed for the aortic arch and thoracoabdominal indications in Japan?
How will the launch of new endovascular devices affect the market?
The penetration of endovascular treatment methods for aortic repair is growing.
What are the main drivers and limiters of growth in the Japanese endovascular aortic repair device market?
Which indication has seen the highest penetration of endovascular treatments?
For which indications will uptake of endovascular aortic repair procedures be limited and why?
Biennial MHLW reimbursement cuts will continue to affect the Japanese aortic repair device market.
Which segments and product types will be most severely impacted by the MHLW reimbursement cuts?
To what degree will reimbursement cuts be compounded by market competition?
Changes in the regulatory landscape will impact the Japanese aortic repair device market.
Which aortic repair devices were the first to be evaluated under HTAs?
How will increasing emphasis on cost-effectiveness data for Japanese reimbursement decisions impact the aortic repair device market?
Already a Client? Log in to access this report.
Megha Maheshwari is a principal analyst within the Cardiovascular Medtech Insights team at Decision Resources Group, specializing in interventional cardiology, aortic repair, and coronary artery bypass graft device markets. In addition to a postgraduate diploma in Hospital Administration with a Certificate in International Medical Tourism and an Associate's degree in Nutrition and Child Care, Megha holds a Bachelor's degree in Physiotherapy from Hemwati Nandan Bahuguna Garhwal University and an MBA in Healthcare IT from NIMS University.